Amanda Fernandes Klajn Maycá
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Amanda Fernandes Klajn Maycá has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Ana Leticia Fornari Caprara
Neurology Department, Cooper Norcross Health, Camden, NJ 08103, USA, USA
1 shared publication - Bruna Amanda Girardi
Biochemical Toxicology Graduate Program Universidade Federal de Santa Maria, UFSM Santa Maria Brazil
1 shared publication - Carlos Fernando Mello
Graduation Program in Pharmacology, Center of Health Sciences, Federal University of Santa Maria, Santa Maria, RS 97105-900, Brazil
1 shared publication - Carolina Matté Dagostini
Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre RS, Brazil
1 shared publication - Fernanda Rossatto Temp
Pharmacology Graduate Program Universidade Federal de Santa Maria UFSM Santa Maria Brazil
1 shared publication - Jamir Pitton Rissardo
Neurology Department, Cooper Norcross Health, Camden, NJ 08103, USA, USA
1 shared publication
Latest Publications
- 5 November 2026
- Published by Wiley in Movement Disorders Clinical Practice
Changes in Clinical Outcomes and Peripheral Cytokines during Duloxetine Add‐on Therapy in Parkinson's Disease
Background: Neuroinflammation is implicated in Parkinson's disease (PD), and antidepressants may have anti‐inflammatory and motor benefits. The effects of duloxetine on inflammatory biomarkers and clinical outcomes in PD remain unclear. Objectives: To assess changes in motor symptoms, quality of life, and serum cytokines during add‐on duloxetine treatment in PD. Methods: Seventeen patients with PD without other chronic inflammatory diseases received add‐on duloxetine for 8 weeks in an open‐label, uncontrolled trial. Clinical outcomes included Unified Parkinson's Disease Rating Scale (UPDRS), modified Hoehn and Yahr (HY), and Parkinson's Disease Questionnaire‐39 (PDQ‐39) scores. Serum TNF‐α, IL‐1β, IL‐6, and IL‐10 levels were measured at baseline and follow‐up. Results: UPDRS, activities of daily living, and PDQ‐39 scores decreased during treatment. Ten patients achieved ≥5‐point UPDRS reductions. TNF‐α, IL‐1β, and IL‐6 decreased, whereas IL‐10 increased after treatment. Conclusions: Add‐on duloxetine was associated with changes in clinical outcomes and inflammatory markers in patients with PD.
- 5 November 2026
- Published by Wiley in Movement Disorders Clinical Practice
Changes in Clinical Outcomes and Peripheral Cytokines during Duloxetine Add‐on Therapy in Parkinson's Disease
Background: Neuroinflammation is implicated in Parkinson's disease (PD), and antidepressants may have anti‐inflammatory and motor benefits. The effects of duloxetine on inflammatory biomarkers and clinical outcomes in PD remain unclear. Objectives: To assess changes in motor symptoms, quality of life, and serum cytokines during add‐on duloxetine treatment in PD. Methods: Seventeen patients with PD without other chronic inflammatory diseases received add‐on duloxetine for 8 weeks in an open‐label, uncontrolled trial. Clinical outcomes included Unified Parkinson's Disease Rating Scale (UPDRS), modified Hoehn and Yahr (HY), and Parkinson's Disease Questionnaire‐39 (PDQ‐39) scores. Serum TNF‐α, IL‐1β, IL‐6, and IL‐10 levels were measured at baseline and follow‐up. Results: UPDRS, activities of daily living, and PDQ‐39 scores decreased during treatment. Ten patients achieved ≥5‐point UPDRS reductions. TNF‐α, IL‐1β, and IL‐6 decreased, whereas IL‐10 increased after treatment. Conclusions: Add‐on duloxetine was associated with changes in clinical outcomes and inflammatory markers in patients with PD.
- Open Access
- 25 January 2026
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 84 (01) , 001-004
Diagnostic challenges in dengue encephalitis: subtle imaging findings and initially negative laboratory test in a kidney transplant recipient
Dengue encephalitis is an uncommon neurological complication of dengue virus infection. In immunocompromised patients, such as solid organ transplant recipients, the clinical presentation may be atypical and nonspecific, posing significant diagnostic and therapeutic challenges. We report a clinical case and use it as a framework to discuss key considerations for suspicion of dengue encephalitis. Topics include optimal timing for clinical suspicion, essential differential diagnoses, and the most appropriate diagnostic strategies. Emphasis is placed on the correct interpretation of cerebrospinal fluid findings and recognition of subtle brain magnetic resonance imaging changes that may support the diagnosis. The discussion also reviews current evidence on dengue encephalitis in immunocompromised populations, highlighting implications for timely diagnosis and management in this vulnerable group.
- 25 January 2026
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 84 (01) , 001-004
Open AccessDiagnostic challenges in dengue encephalitis: subtle imaging findings and initially negative laboratory test in a kidney transplant recipient
Dengue encephalitis is an uncommon neurological complication of dengue virus infection. In immunocompromised patients, such as solid organ transplant recipients, the clinical presentation may be atypical and nonspecific, posing significant diagnostic and therapeutic challenges. We report a clinical case and use it as a framework to discuss key considerations for suspicion of dengue encephalitis. Topics include optimal timing for clinical suspicion, essential differential diagnoses, and the most appropriate diagnostic strategies. Emphasis is placed on the correct interpretation of cerebrospinal fluid findings and recognition of subtle brain magnetic resonance imaging changes that may support the diagnosis. The discussion also reviews current evidence on dengue encephalitis in immunocompromised populations, highlighting implications for timely diagnosis and management in this vulnerable group.